Telacebec (Q203) is a new anti-tubercular drug with extremely potent activity against 25
Baltimore, Maryland, USA a Introductiondetection: 1 CFU). In the R 10 C 100 group relapse was assessed only in mice treated for 4 weeks. 114
Three mice experienced a rebound in footpad swelling during the 6-month follow-up period. 115
Two of these mice required euthanasia before the planned relapse endpoint because one or both 116 footpads had deteriorated beyond a lesion index of 3. Overall, the relapse rate in the R 10 C 100 117 group was 25%, with 4/16 footpads positive for CFU (p=0.10 vs. other groups with 0/16 118 relapses). 119 120
Study 2: To determine the dose-ranging activity of Q203 alone and in combination with standard 121 and high-dose rifampin, including the extended activity after treatment discontinuation. 122
After showing that Q203 alone at 5-10 mg/kg/day renders mouse footpads culture-negative and 123 combinations of RIF+Q203 sterilize footpads with just 2 weeks of treatment, we evaluated a 124 lower dose range and shorter durations of Q203, alone and in combination with RIF. We also 125 assessed the plasma PK of Q203 after single doses of 0.5, 2 and 10 mg/kg doses, and determined 126 plasma concentrations of Q203 at 3-4 days and 2 and 4 weeks after stopping treatment. 127
Pharmacokinetics: The single dose PK results for Q203 are shown in Fig. 3 . Q203 had a t max of 2 128 hrs. C max values after 0.5, 2 and 10 mg/kg doses were 0.05, 0.17 and 0.92 µg/ml respectively, 129
indicating that even at the lowest dose, the C max was well above the MIC of 0.000075-0.00015 130 µg/ml. Plasma AUC values indicated dose-proportional exposures up to 2 mg/kg. After 1 week 131 of treatment, in the lowest dose group tested, Q203 at 0.5 mg/kg, the mean plasma concentration 132 of Q203 at 72 hrs post-dose was 0.073 ± 0.024 µg/ml and in the groups treated for 2 weeks, at 96 133 hrs post-dose, it was 0.052 ± 0.013 µg/ml (Supplementary Table S2 ). In both these groups, the 134 concentrations gradually declined during the 4-week follow-up period, but remained higher than 135 the MIC. With higher doses of Q203, more accumulation was seen, and it increased with the 136 duration of treatment, with plasma concentrations in mice treated for 2 weeks almost twice as 137 high as in those treated for one week. In mice treated with RIF+Q203, Q203 concentrations were 138 similar to those in mice treated with Q203 alone indicating no large effect of RIF on Q203 139
concentrations. 140
Footpad swelling: At the start of treatment, mice had a median swelling grade of 2 (Fig. 4) . In 141 untreated mice, the swelling increased to grade 2.5 and grade 3 at end of Weeks 1 and 2, 142 respectively. All untreated mice required euthanasia at this point. In mice treated with R 10 C 100 , 143
there was a marginal decrease to 1.5 at Week 1 (Figs. 4A and 4B) and a further decrease to 0.5 at 144
Week 2 ( treated with RIF 10 mg/kg alone for 1 week, there was slight decline in swelling after peaking at 147 week 1 (Fig. 4A) . At the end of 4 weeks, when all mice were sacrificed for CFU, the median 148 swelling grade was 1.5, with one mouse showing grade 3 swelling. In mice treated with RIF 10 149 mg/kg for 2 weeks (Fig. 4C) , the response to treatment was better than in mice treated for only 1 150 week. After 2 weeks of treatment, the swelling had reduced to median swelling grade of 1.5 and 151 gradually decreased to 0.5 after 4 more weeks of follow-up without treatment. In mice treated 152 with RIF 20 mg/kg, the response to treatment was similar to that of 10 mg/kg group. As in the 153 previous experiment, footpad swelling decreased rapidly in Q203-treated groups. All doses of 154 Q203 whether given alone or in combination with RIF at 10 or 20 mg/kg rapidly reduced footpad 155 swelling. After 1 week of treatment, the swelling reverted to baseline in most mice, while some 156 mice showed residual swelling (swelling grade < 1) (Fig. 4A) . Irrespective of whether the 157 treatment was stopped after one week or continued for an additional week, the footpads 158 continued to improve during the follow-up period, with almost all footpads returning to baseline 159 by Week 2 and remaining free of swelling. 160
Footpad CFU counts: At the start of treatment (D0), mean footpad CFU counts were 5.40 ± 0.39 161 log 10 . They increased to 5.71 ± 0.23 at Week 1 (Figs. 5A and 5B) and 5.98 ± 0.23 at Week 2 in 162 untreated mice (Figs. 5C and 5D) . 163
In mice treated with R 10 C 100 , CFU counts decreased to 4.79 ± 0.32 log 10 at Week 1 and 164 3.50 ± 0.48 log 10 at Week 2. Continued killing was observed after stopping treatment, 165 corroborating the observed reductions in footpad swelling during the 4-week follow-up period 166 (Figs. 5C and 5D). In mice receiving RIF at 10 or 20 mg/kg, little change in CFU was seen after 167 one week of treatment or during the 4-week follow-up period, again similar to what was seen in 168 footpad swelling ( Figure 5A ). Increasing the duration of RIF treatment to two weeks resulted in a 169 1.5 log 10 CFU reduction in both dosage groups (Fig. 5C ) and continued decreases to 1.24 ± 0.23 170 and 1.78 ± 0.83 4 weeks after completing treatment in the R 10 and R 20 groups, respectively. 171 A modest dose-dependent effect was observed in mice treated with Q203 alone for one 172 week, with CFU counts falling to 5.03 ± 0.43, 3.93 ± 0.58, and 4.25 ± 0.42 log 10 CFU in those 173 receiving 0.5, 2 and 10 mg/kg doses, respectively. With the exception of R 20 Q 2 (Fig. 5B ) (p= 174 0.002), the reductions in CFU at Week 1 were not significantly better than the R 10 C 100 control. 175
However, Q203 treatment for one week resulted in more dramatic reductions in CFU counts after 176 treatment cessation. CFU counts in Q 0.5 -treated mice fell to 1.69 ± 0.64 and 0.48 ± 1.48 log 10 177 CFU after 2 and 4 weeks of follow-up. No CFU were detected after 2 or 4 weeks of follow-up in 178 mice treated with Q 2 or 4 weeks after treatment with Q 10 (Fig. 5A ). Comparisons to the R 10 C 100 179 group at W1+2 and W1+4 time points was not possible since we did not include these time 180 points for this group. However, all groups receiving Q203 doses ≥ 2 mg/kg had significantly 181 lower CFU counts at the W1+2 (p ≤ 0.0006) and W1+4 (p < 0.0001) time points than R 10 C 100 182 controls had at the W2+2 and W2+4 time points, respectively. 183
In mice treated for 2 weeks with Q203, a more prominent dose-response relationship was 184 observed. In mice treated with Q203 at 10 mg/kg, the mean log 10 CFU count was only 0.24 ± 185 0.38, with 4/6 pads negative. No CFU were detected in footpads in any Q203-treated group at 2 186 and 4 weeks follow-up (Fig. 5C ). At this point all Q203-containing regimens were significantly 187 better when compared with the R 10 C 100 controls (p ≤ 0.05). Little information about the PK of Q203 in humans exists in the public domain (18) and 214 published PK data from mice report very different drug exposures for the same or similar doses 215 (13, 17). To better understand the dose-response profile of Q203 in mice and the human 216 equivalent doses of the Q203 doses evaluated in our model, we evaluated Q203 doses ranging 217 from 0.5 to 10 mg/kg and included PK analyses. Remarkably, Q203 alone at 2 mg/kg rendered 218 mouse footpads culture-negative after just 5 daily doses. The median plasma C max and AUC 0-72h 219 values after a single oral dose in mice were 0.17 µg/ml and 4.3 µg-h/ml, respectively. These 220 results are in line with mouse PK results from Pethe et al (13) and, more importantly, comparable 221 to the plasma C max and AUC 0-inf values of 0.38 µg/ml and 6.3 µg-h/ml, respectively, after a single 222 dose of 100 mg in fed human (18) subjects. Considering that we observed dose-proportional PK 223 in mice, Q203 doses of 2-10 mg/kg in mice likely correspond well to the daily doses of 100-300 224 mg that were recently reported to be well tolerated and safe in phase 1 trials and in TB patients 225 over 14 days of dosing in a recent phase 2a trial (21), provided that the drug is administered with 226 food. Therefore, we predict that these doses can safely shorten treatment of BU to 5 doses or 227
less. 228
The extreme treatment-shortening effects of Q203 we observed in mice were the result of 229 persistent killing of M. ulcerans that extended well beyond the end of dosing, even at the lowest 230 dose of 0.5 mg/kg. This persistent killing is likely a function of multiple phenomena: 231 exceptionally potent activity (e.g., very low MIC), low clearance (e.g., long plasma half-life), 232 favorable partitioning into tissue (e.g., lung:plasma concentration ratio of 2-3) (13), and a post-233 antibiotic effect (e.g., continued antimicrobial effect against M. ulcerans after plasma 234 concentrations fall below MIC). While the roles of the first 2 phenomena are self-evident from 235 the PK/PD data generated in Study 2, more evidence is needed to confirm the partitioning of 236 Another surprising finding of these experiments was that the addition of RIF did not 247 significantly increase the treatment efficacy of Q203. In fact, other than some additive effects of 248 RIF with Q203 at 0.5 mg/kg at the Week 1 and Week 2 time points, there were hints of modest 249 antagonistic effects of RIF at each Q203 dose level, especially 2 mg/kg and above. Our PK 250 results did not show any significant differences in Q203 plasma concentrations when RIF and 251 Q203 were co-administered when compared to Q203 given alone. These results raise the 252 prospect of using Q203 as monotherapy, a scenario that may be defensible because the 253 spontaneous frequency of Q203 resistance mutations in M. ulcerans appears to be very low (17) 254 and M. ulcerans is not transmitted from person-to-person, making resistance development both 255 unlikely to occur as well as unlikely to have any impact beyond the affected individual. 256
In summary, we have demonstrated the extraordinary potential of Q203 to reduce the 257 duration of treatment for BU to 1 week (or 5 doses of 2-5 mg/kg) in our mouse footpad infection 258 model. As these doses appear to be a good representation of doses recently tested successfully in 259 humans, they warrant consideration for further evaluation in clinical trials for BU treatment. 
Study 1. 281
Mice were randomized to one of the seven treatment groups (Supplemental Table S4 ). Control 282 regimens included R 10 C 100 , Q 5 alone or Q 10 alone, where the subscript represents the dose in mg 283 per kg of body weight. Test regimens consisted of either R 10 Q 5 , R 20 Q 5 , R 10 Q 10 or R 20 Q 10 , and 284 mice were treated for either 2 or 4 weeks. Mice treated with Q alone were treated for only 2 285 weeks since they were only included in the experiment to inform the contribution of Q203 and 286 we did not initially intend to explore the use of Q203 alone as monotherapy. CFU counts were 287 performed after 1, 2 and 4 weeks of treatment to determine the response to treatment. To 288 determine the sterilizing activity of each test regimen, mice were held without treatment for six 289 months after completing 2 and 4 weeks of treatment. Relapse assessment for the R 10 C 100 control 290 group was done only after 4 weeks of treatment. 291 Study 2. Mice were randomized to one of 12 treatment groups, which included Q203 at doses of 292 0.5, 2 and 10 mg/kg given alone or in combination with RIF at 10 or 20 mg/kg. Control groups 293 were untreated or received R 10 or R 20 alone, or R 10 C 100 , which is the current standard of care 294 (Supplemental Table S5 ). Mice were treated for either 1 or 2 weeks. R 10 Q 2 group mice were 295 accidentally gavaged with Q at 10 mg/kg dose on Day 4 of treatment. These mice were not 296 gavaged on the following day and therefore received a cumulative dose of 16 mg/kg instead of 297 the intended 10 mg/kg dose for the first week. By the end of 2 weeks of treatment, these mice 298 had received a total dose of 26 mg/kg instead of the intended 20 mg/kg dose. Footpad CFU 299 counts were done at treatment completion and also at 2 and 4 weeks after stopping treatment in 300 each treatment group to determine the continued bactericidal activity of Q203-containing 301
regimens. 302
Pharmacokinetics. Intensive PK evaluation was done for groups receiving Q203 alone and in 303 combination with RIF. After a single dose on D0, small-volume blood samples were collected in 304 EDTA-containing tubes at 1, 2, 4, 6, 9, 24, 48 and 72 hrs post-dose from the submandibular vein. 305
To assess the clearance of Q203 after stopping treatment, samples were obtained at 72 hrs after 306 the final dose in mice treated for 1 week and 96 hrs after the final dose in mice treated for 2 307
weeks. Blood samples were also obtained at the 2-and 4-week follow time points in mice treated 308 with Q203 alone for 1 and 2 weeks, and in mice treated with RIF+Q203 for 2 weeks.Samples 309 from the R 10 Q 2 group were excluded because mice in this group were accidentally gavaged with 310 10 mg/kg dose on Day 4 of treatment. 311
Evaluation of treatment response. Treatment outcomes were evaluated based on (i) decrease in 312 footpad swelling, denoted as swelling grade, and (ii) decrease in CFU counts. The swelling grade 313 was was scored as described previously (7). Briefly, the presence and the degree of inflammatory 314 swelling of the infected footpad were assessed weekly and scored from 0 (no swelling) to 4 315 (inflammatory swelling extending to the entire limb) for all surviving mice. For CFU counts, six 316 footpads (from three mice) were evaluated on the day after infection (D-42), and at the start of 317 treatment (D0) to determine the infectious dose and the pretreatment CFU counts, respectively. 318
The response to treatment was determined by plating 6 footpads (from 3 mice) from each 319 treatment group at predetermined time points. Footpad tissue was harvested after thorough 320 disinfection with 70% alcohol swabs and then homogenized by fine mincing before suspending 321 in sterile phosphate buffered saline (PBS). Ten-fold serial dilutions and undiluted fractions of 322 homogenate were plated in 0.5 ml aliquots on selective 7H11 agar and incubated at 32°C for up 323 to 12 weeks before CFU were enumerated. In the second study, homogenates were plated on 324 7H11 agar supplemented with 10% OADC and 5% bovine plasma albumin to reduce any 325 potential effects of Q203 carryover due to its long half-life (23). 326
To determine the sterilization activity of each test regimen in Study 1, mice were held for relapse 327 assessment for 6 months after completing 2 and 4 weeks of treatment. Results were compared to 328 those from mice treated with R 10 C 100 for 4 weeks. Footpads were inspected every 2 weeks for 329 any signs of re-swelling after stopping treatment. When re-swelling was observed, mice were 330 sacrificed when the swelling reached a lesion index ≥ 3 and the footpads were harvested and 331 plated for CFU counts. At the end of the 6-month follow-up period, all remaining mice were 332 sacrificed and their footpads (16 footpads in each group) were harvested and plated for CFU. 333
Study 2, instead of relapse assessment at 6 months, we held mice without treatment for an 334 additional 2 or 4 weeks after treatment completion before harvesting and plating for 335 determination of CFU counts. 336 Statistical analysis. GraphPad Prism 6 was used to compare mean CFU counts in Q203-337 containing groups to the R 10 C 100 control group using two-way analysis of variance with 338
Bonferroni's post-test to adjust for multiple comparisons. Proportions were compared using 339 response, and although CFU counts at Week 1 were not significantly different than RC controls, 534 more dramatic reductions occurred during the 4 week follow-up period after stopping treatment. 535
All Q-containing regimens except Q 0.5 were significantly better after 1 week of treatment than 536 RC treatment for 2 weeks. After 2 weeks of treatment, all Q-containing regimens were 537 significantly better than RC control after 2 weeks and rendered footpads negative at follow-up 2 538 weeks after stopping treatment. 558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587 
